Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives

Liver International

Volumn 36, Issue , 2016, Pages 47-57

  Asselah, Tarik ^a   Boyer, Nathalie ^a   Saadoun, David ^a   Martinot Peignoux, Michele ^a   Marcellin, Patrick ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Dasabuvir grazoprevir; Elbasvir; Ledipasvir; Ombitasvir; Paritaprevir; Sofosbuvir; Velpatasvir

Indexed keywords

DASABUVIR; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; SOFOSBUVIR PLUS VELPATASVIR; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; CARBAMIC ACID DERIVATIVE; FLUORENE DERIVATIVE; FUSED HETEROCYCLIC RINGS; IMIDAZOLE DERIVATIVE; LEDIPASVIR; MACROCYCLIC COMPOUND; MK-5172; NS-5 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE; SOFOSBUVIR; SULFONAMIDE; URACIL; VELPATASVIR; VIRAL PROTEIN;

ANTIVIRAL THERAPY; HEPATITIS C; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANILIDES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; BENZOFURANS; CARBAMATES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; IMIDAZOLES; MACROCYCLIC COMPOUNDS; PROTEASE INHIBITORS; QUINOXALINES; SOFOSBUVIR; SULFONAMIDES; URACIL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84952815567     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13027     Document Type: Review

References (33)

1. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36(5 Suppl. 1): S47-56.
2. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
3. Saadoun D, Asselah T, Resche-Rigon M, et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology 2006; 43: 1337-45.
4. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Suppl. 1): 88-102.
5. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-25.
6. Estrabaud E, Lapalus M, Broët P, et al. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C. J Virol 2014; 88: 6394-402.
7. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-9.
8. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.
9. Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection. Liver Int 2015; 35(Suppl. 1): 56-64.
10. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): 69-78.
11. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2014; 15: 121-30.
12. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
13. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
14. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
15. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
16. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
17. Gilead Sciences Ltd. Harvoni (ledipasvir/sofosbuvir), Summary of Product Characteristics, November 2014.
18. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-14.
19. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.
20. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.
21. Everson GT, Dusheiko G, Coakley E, et al. Integrated efficacy analysis of four phase 3 studies in HCV genotype 1a-infected patients treated with ABT-450/r/ombitasvir and dasabuvir with or without ribavirin. Hepatology 2014; 60(Suppl.): 239-240A.
22. Colombo M, Weiland O, Cohen DE, et al. SVR12 rate of 98.6% in 992 HCV genotype 1b-infected patients treated with ABT-450/r/ombitasvir and dasabuvir with or without ribavirin. Hepatology 2014; 60(Suppl.): 1131A.
23. AbbVie, Ltd. Viekirax Tablets (Ombitasvir/Paritaprevir/Ritonavir) Summary of Product Characteristics. Maidenhead, UK: AbbVie, Ltd., 2015.
24. AbbVie, Ltd. Exviera Tablets (Dasabuvir) Summary of Product Characteristics. Maidenhead, UK: AbbVie, Ltd., 2015.
25. Abergel A, Loustaud-Ratti V, Metivier S, et al. Ledipasvir/Sofosbuvir Treatment Results in High SVR Rates in Patients With Chronic Genotype 4 and 5 HCV Infection. 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22-26, 2015. Abstract O056.
26. Hezode C, Asselah T, Reddy KR, et al. A randomized, open-label study of ombitasvir and ABT-450/r with or without ribavirin in treatment-naidotlessve and treatmentexperienced patients with chronic hepatitis C virus infection (PEARL-I): results in patients with genotype 4 infection. Lancet 2015; 385: 2502-9.
27. Gilead Press Release. September 21, 2015.
28. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection, submitted.
29. Foster GR, Afdhal N, Roberts SK, et al., Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection, submitted.
30. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet, in press.
31. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163: 1-13.
32. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-32.
33. Asselah T, Perumalswami PV, Dieterich D. Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity. Liver Int 2014; 34: 1447-51.